In this article, we will be taking a look at the 5 Best Low-Priced Pharma Stocks to Buy Right Now. If you wish to see the full list, visit 12 Best Low-Priced Pharma Stocks to Buy Right Now.

5. BioAge Labs, Inc. (NASDAQ:BIOA)

Number of Hedge Fund Holders: 35

Stock Price: $22.83

BioAge Labs, Inc. (NASDAQ:BIOA) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 16 that BIOA announced the dosing of the first participant in QUELL-CV, a Phase 2 proof-of-concept study evaluating BGE-102. The investigational therapy is a potent, orally available, brain-penetrant small molecule NLRP3 inhibitor designed for once-daily administration. BIOA is developing BGE-102 with cardiovascular risk reduction as its lead therapeutic focus. The initiation of the QUELL-CV trial represents progress in advancing the company’s clinical program targeting cardiovascular disease pathways.

BioAge Labs, Inc. (NASDAQ:BIOA) previously reported its first quarter 2026 financial results on May 8, highlighting the continued advancement of its therapeutic programs focused on cardiometabolic diseases and aging biology. The company shared progress from its BGE-102 program, where Phase 1 data showed strong reductions in hsCRP levels, including median decreases of 86% from baseline across evaluated dose groups. BGE-102 was well tolerated with no serious adverse events reported. BIOA plans to begin a Phase 2 dose-ranging study in participants with elevated cardiovascular risk in mid-2026. During the quarter, collaboration revenue reached $2.8 million, while research and development expenses increased to $20.4 million. As of March 31, 2026, BIOA held approximately $384.9 million in cash, cash equivalents, and marketable securities.

BioAge Labs, Inc. (NASDAQ:BIOA) is a clinical-stage biopharmaceutical company using AI and longevity research to develop therapies targeting aging-related metabolic and cardiovascular diseases.

4. Organon & Co. (NYSE:OGN)

Number of Hedge Fund Holders: 37

Stock Price: $13.48

Organon & Co. (NYSE:OGN) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 22 that OGN announced the completion of a global licensing agreement with Sebela Pharmaceuticals, securing exclusive rights to MIUDELLA, a hormone-free copper intrauterine device. Approved by the U.S. FDA in February 2025, MIUDELLA represents the first hormone-free copper IUD launched in the U.S. in more than four decades. The device is designed to prevent pregnancy for up to three years and offers 99% effectiveness. MIUDELLA incorporates SLIMSERT technology, featuring a flexible frame and preloaded insertion system with a 3.7mm tapered tube. The product is expected to become commercially available in late 2026.

Separately, on June 18, Organon & Co. (NYSE:OGN) and Samsung Bioepis announced an expansion of their development and commercialization partnership, with Organon gaining exclusive commercialization rights in Canada for Pyzchiva, a biosimilar referencing Stelara (ustekinumab). The therapy is intended for multiple inflammatory conditions, including plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Under the agreement, Samsung Bioepis will continue managing development, manufacturing, and regulatory responsibilities, while Organon will lead commercial activities in Canada. The expansion increases their Canadian biosimilar collaboration portfolio from five to six products, with Pyzchiva expected to launch in 2026.

Organon & Co. (NYSE:OGN) is a global healthcare company focused on women’s health, biosimilars, and established medicines, offering a portfolio of over 70 products across more than 140 markets.

3. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Number of Hedge Fund Holders: 40

Stock Price: $7.40

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 11 that XERS announced that the USPTO issued a notice of allowance for U.S. Patent Application No. 17/151,405, covering compositions and methods of use related to its Keveyis product. The allowed claims were determined to meet patentability requirements and are expected to advance toward patent issuance after completing standard administrative procedures. Following approval, Xeris plans to submit the patent for inclusion in the FDA’s Orange Book listing. If issued and maintained through required filings and fees, the new patent is expected to extend intellectual property protection for Keveyis through 2039.

Simultaneously, on June 11, Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) entered into privately negotiated exchange agreements with holders of its 8.00% Convertible Senior Notes due 2028. Under the agreements, the company plans to retire approximately $23 million in principal amount of notes through a combination of cash payments and common stock issuance. The number of shares issued will depend on the volume-weighted average trading price of XERS common stock during a 21-day averaging period beginning June 11. Based on an assumed average price of $6.71, XERS expects to issue about 4.6 million shares. After completion, approximately $10.5 million of notes will remain outstanding.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a commercial-stage biopharmaceutical company developing ready-to-use, room-temperature stable therapies for endocrine and neurological disorders.

2. Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Number of Hedge Fund Holders: 52

Stock Price: $34.22

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 18 that Jefferies analyst Dennis Ding maintained a Buy rating and a $40 price target on TEVA following recent share weakness. The analyst noted that the decline was largely influenced by broader market factors and investor reactions to management comments regarding the company’s vitiligo program, along with a clinical trial update shifting the expected primary completion date. After discussions with Teva’s investor relations team, confidence in the vitiligo program remained unchanged, with data still expected shortly after the July 4 weekend. Jefferies continues to view the recent pullback as an opportunity and remains positive on the shares.

Separately, on June 5, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced new real-world findings from a decentralized study examining the impact of Huntington’s disease chorea on patients and caregivers, along with the effects of AUSTEDO and AUSTEDO XR on symptom management. The data showed that treatment was associated with improvements in chorea symptoms and multiple quality-of-life areas. Presented at the Advanced Therapeutics in Movement & Related Disorders Congress, the study found that 74% of patients reported improved movements after starting therapy. Additionally, more than 85% of patients noted progress toward daily activity and social goals, while 77% of caregivers reported improvements in social and emotional well-being measures.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is the world’s largest generic drug manufacturer, providing affordable medicines and specialty therapies across nearly 60 markets with a global healthcare presence.

1. Bristol-Myers Squibb Company (NYSE:BMY)

Number of Hedge Fund Holders: 83

Stock Price: $55

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 15 that RBC Capital analyst Trung Huynh noted that the proposed changes to the Medicare Drug Price Negotiation Program could introduce potential risks for companies, including Bristol-Myers Squibb Company (NYSE:BMY) and several others. The proposal would make the program permanent starting in 2029 and introduce stricter requirements around fixed-combination lifecycle strategies. However, the analyst highlighted that legal challenges, regulatory exemptions, and diversified product portfolios may reduce the overall impact on these companies.

In a separate regulatory update on June 1, BMY announced that the FDA accepted its supplemental New Drug Application for Camzyos as a potential treatment for adolescents with symptomatic obstructive hypertrophic cardiomyopathy. The application received Priority Review status, with the FDA assigning a PDUFA target action date of September 30, 2026. If approved, Camzyos would become the first cardiac myosin inhibitor available for adolescent patients with oHCM. The therapy is currently approved for adults with symptomatic NYHA class II-III oHCM to improve symptoms and functional capacity, with use reported among thousands of healthcare providers and patients across the U.S.

Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company developing innovative medicines, including small molecules, biologics, and CAR-T therapies for cancer, cardiovascular, and immune-related diseases.

READ NEXT: 10 Best Future Stocks to Buy and Hold for 10 Years and 10 Most Promising Long-Term Stocks to Buy According to Analysts.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.